Acadia Pharmaceuticals vs Corcept Therapeutics
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Acadia Pharmaceuticals and Corcept Therapeutics side by side, using each one’s latest annual report. Here is what stands out:
- Acadia Pharmaceuticals is the larger business, with $1.1B of revenue in fiscal 2025 against $761M for Corcept Therapeutics.
- Corcept Therapeutics grew revenue faster (12.8%, against 11.9%).
- Acadia Pharmaceuticals kept more of each dollar of sales as operating profit (9.8% operating margin, against 5.9%).
- Corcept Therapeutics turned more of its sales into free cash flow (18.6% FCF margin, against 9.8%).
Who comes out ahead
Of the 8 measures where higher (or lower) is clearly better, how many each company leads.
Acadia Pharmaceuticals
ACAD
5/8
5-year growthOperating marginNet marginReturn on equityShare count change
Corcept Therapeutics
CORT
3/8
Revenue growthGross marginFCF margin
Side by side
Best in the row
| Latest fiscal year | ACAD FY25 | CORT FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.4B | $10.2B |
| Revenue | $1.1B | $761M |
| Free cash flow | $105M | $142M |
| Net income | $391M | $99.7M |
| Growth | ||
| Revenue growth | 11.9% | 12.8% |
| 5-year growth | 19.4% | 16.6% |
| Share count change | 2.1% | 5.7% |
| Profitability | ||
| Gross margin | 91.7% | 98.3% |
| Operating margin | 9.8% | 5.9% |
| Net margin | 36.5% | 13.1% |
| FCF margin | 9.8% | 18.6% |
| Return on capital | — | 15.7% |
| Return on equity | 39.9% | 15.0% |
| Balance sheet | ||
| Net debt | — | −$372M |
| Net debt / EBITDA | — | −8.1x |
| Dividends and buybacks | $0.0M | $173M |
| Valuation & quality | ||
| P/E | 8.8x | — |
| Piotroski F-score | — | 3 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.